What is Flexion Therapeutics Debt-to-Equity?
Flexion Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $1.6 Mil. Flexion Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $255.8 Mil. Flexion Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2021 was $-82.4 Mil.
Flexion Therapeutics's debt to equity for the quarter that ended in Sep. 2021 was -3.13.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Flexion Therapeutics's Debt-to-Equity or its related term are showing as below:
FLXN'
s Debt-to-Equity Range Over the Past 10 Years
Min: -73.99 Med: 0.16 Max: 27.94
Current: -3.13
During the past 10 years, the highest Debt-to-Equity Ratio of Flexion Therapeutics was 27.94. The lowest was -73.99. And the median was 0.16.
Flexion Therapeutics Debt-to-Equity Historical Data
The historical data trend for Flexion Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flexion Therapeutics Debt-to-Equity Chart
|
Flexion Therapeutics Annual Data
|
|
Trend |
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.16 |
0.62 |
1.44 |
-10.07 |
-13.89 |
|
Flexion Therapeutics Quarterly Data
|
|
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-73.99 |
-13.89 |
-5.93 |
-4.08 |
-3.13 |
Competitive Comparison of Flexion Therapeutics's Debt-to-Equity
For the Drug Manufacturers - Specialty & Generic subindustry, Flexion Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flexion Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Flexion Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Flexion Therapeutics's Debt-to-Equity falls into.
Flexion Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Flexion Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as
Flexion Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flexion Therapeutics (Flexion Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
10 Mall Road, Suite 301, Burlington, MA, USA, 01803
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.
Executives
| Mark S. Levine |
officer: General Counsel |
1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
| Kerry Wentworth |
officer: Chief Regulatory Officer |
AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421 |
| Christina Willwerth |
officer: Chief Strategy Officer |
C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803 |
| David Arkowitz |
officer: Chief Financial Officer |
C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
| Melissa Layman |
officer: Chief Commercial Officer |
C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803 |
| Scott Kelley |
officer: Chief Medical Officer |
C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505 |
| Elizabeth Kwo |
director |
C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
| Michael D. Clayman |
director, officer: President and CEO |
C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
| Alan Milinazzo |
director |
C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078 |
| Scott A Canute |
director |
FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
| C Ann Merrifield |
director |
|
| Heath Lukatch |
director |
326 BOLLAY DRIVE, GOLETA CA 93117 |
| Samuel D Colella |
director, 10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Patrick J Mahaffy |
director |
C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
| Mark Stejbach |
director |
C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403 |
Flexion Therapeutics (Flexion Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLXN has been successfully added to your